Skip to main content

Table 2 Contribution matrix for any mood episode relapse (the complete contribution matrix is shown on pp. 84–85 of the Appendix in Miura et al. [4])

From: Using the contribution matrix to evaluate complex study limitations in a network meta-analysis: a case study of bipolar maintenance pharmacotherapy review

 

Number of comparisons

PLB vs LIT

PLB vs VPA

PLB vs LTG

PLB vs IMP

PLB vs FLX

PLB LIT+IMP

PLB vs ARP

PLB vs OLZ

PLC vs QTP

PLB RisLAI

PLB vs PAL

LIT vs VPA

LIT vs CBZ

LIT vs LTG

LIT vs IMP

LIT vs FLX

LIT vs LIT+IMP

LIT vs LIT+VPA

LIT vs LIT+OXC

LIT vs OLZ

LIT vs QTP

VPA vs LIT+VPA

VPA vs VPA+ARP

LTG vs VPA+LTG

LTG vs ARP+LTG

IMP vs LIT+IMP

OLZ vs RisLAl

Any mood eplaode

 PLB vs LIT

10

27.2

5.3

13.7

2.3

 

0.2

0.0

4.9

5.7

2.1

0.0

3.1

0.0

13.7

1.8

 

0.7

2.2

0.0

6.9

5.7

2.2

0.0

 

0.0

0.5

2.1

 PLB vs VPA

1

14.2

13.0

7.1

1.2

 

0.1

0.0

2.5

3.0

1.1

0.0

17.0

0.0

7.1

0.9

 

0.4

12.2

0.0

3.6

3.0

12.2

0.0

 

0.0

0.3

1.1

 PLB vs LTG

4

9.9

1.9

56.5

0.8

 

0.1

0.0

1.8

2.0

0.7

0.0

1.1

0.0

17.2

0.6

 

0.3

0.8

0.0

2.5

2.0

0.8

0.0

 

0.0

0.2

0.7

 PLB vs IMP

2

14.8

2.9

7.4

8.1

 

0.5

0.0

2.6

3.1

1.1

0.0

1.7

0.0

7.4

23.9

 

7.9

1.2

0.0

3.7

3.1

1.2

0.0

 

0.0

8.4

1.1

 PLB vs LIT+IMP

1

14.3

2.8

7.1

4.3

 

1.0

0.0

2.5

3.0

1.1

0.0

1.6

0.0

7.1

10.3

 

20.5

1.2

0.0

3.6

3.0

1.2

0.0

 

0.0

14.6

1.1

 PLB vs ARP

1

0.0

0.0

0.0

0.0

 

0.0

100.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

 

0.0

0.0

0.0

0.0

0.0

0.0

0.0

 

0.0

0.0

0.0

 PLB vs. OLZ

2

11.5

2.2

5.8

1.0

 

0.1

0.0

22.5

2.4

9.5

0.0

1.3

0.0

5.8

0.8

 

0.3

0.9

0.0

23.0

2.4

0.9

0.0

 

0.0

0.2

9.5

 PLB vs. QTP

2

14.4

2.8

7.2

1.2

 

0.1

0.0

2.6

23.6

1.1

0.0

1.6

0.0

7.2

0.9

 

0.4

1.2

0.0

3.7

29.4

1.2

0.0

 

0.0

0.3

1.1

 PLB vs RisLAI

2

4.6

0.9

2.3

0.4

 

0.0

0.0

9.0

1.0

49.4

0.0

0.5

0.0

2.3

0.3

 

0.1

0.4

0.0

9.2

1.0

0.4

0.0

 

0.0

0.1

18.2

 PLB vs PAL

1

0.0

0.0

0.0

0.0

 

0.0

0.0

0.0

0.0

0.0

100.0

0.0

0.0

0.0

0.0

 

0.0

0.0

0.0

0.0

0.0

0.0

0.0

 

0.0

0.0

0.0

Manio eplaode

 PLB vs LIT

7

39.4

11.6

9.5

0.8

 

0.4

0.0

0.6

5.9

0.2

0.0

9.4

0.0

9.5

0.7

 

0.5

2.2

0.0

0.8

5.9

2.2

0.0

0.0

0.0

0.1

0.2

 PLB vs VPA

1

23.2

16.3

5.6

0.5

 

0.2

0.0

0.3

3.5

0.1

0.0

21.1

0.0

5.6

0.4

 

0.3

6.4

0.0

0.5

3.5

6.4

0.0

0.0

0.0

0.1

0.1

 PLB vs LTG

3

12.9

3.8

54.3

0.3

 

0.1

0.0

0.2

1.9

0.1

0.0

3.1

0.0

19.3

0.2

 

0.2

0.7

0.0

0.3

1.9

0.7

0.0

0.0

0.0

0.0

0.1

 PLB vs IMP

1

20.4

6.0

4.9

2.5

 

0.6

0.0

0.3

3.1

0.1

0.0

4.9

0.0

4.9

23.8

 

11.0

1.2

0.0

0 4

3.1

1.2

0.0

0.0

0.0

11.6

0.1

 PLB vs LIT+IMP

1

21.3

6.0

4.9

1.4

 

1.1

0.0

0.3

3.0

0.1

0.0

4.8

0.0

4.9

11.3

 

23.3

1.1

0.0

0.4

3.0

1.1

0.0

0.0

0.0

12.7

0.1

 PLB vs ARP

1

0.0

0.0

0.0

0.0

 

0.0

99.9

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

 

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

 PLB vs OLZ

2

1.2

0.4

0.3

0.0

 

0.0

0.0

54.7

0.2

20.1

0.0

0.3

0.0

0.3

0.0

 

0.0

0.1

0.0

2.1

0.2

0.1

0.0

0.0

0.0

0.0

20.1

 PLB vs QTP

2

22.2

6.6

5.4

0.4

 

0.2

0.0

0.3

15.0

0.1

0.0

5.3

0.0

5.4

0.4

 

0.3

1.3

0.0

0.4

35.3

1.3

0.0

0.0

0.0

0.1

0.1

 PLB vs RisLAI

2

0.4

0.1

0.1

0.0

 

0.0

0.0

19.4

0.1

58.5

0.0

0.1

0.0

0.1

0.0

 

0.0

0.0

0.0

0.8

0.1

0.0

0.0

0.0

0.0

0.0

20.2

 PLB vs PAL

1

0.0

0.0

0.0

0.0

 

0.0

0.0

0.0

0.0

0.0

100.0

0.0

0.0

0.0

0.0

 

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

Dapreesive eplaode

 PLB vs LIT

8

46.5

2.3

8.5

0.8

2.2

0.4

0.0

4.3

6.7

0.5

0.0

1.1

0.0

8.5

0.6

2.2

0.5

1.2

0.0

4.9

6.7

1.2

0.0

0.0

0.0

0.1

0.5

 PLB vs VPA

1

21.2

9.1

3.9

0.4

1.0

0.2

0.0

2.0

3.0

0.2

0.0

15.5

0.0

3.9

0.3

1.0

0.2

16.3

0.0

2.2

3.0

16.3

0.0

0.0

0.0

0.1

0.2

 PLB vsLTG

3

20.8

1.1

34.3

0.3

1.0

0.2

0.0

1.9

3.0

0.2

0.0

0.5

0.0

2.8.6

0.3

1.0

0.2

0.5

0.0

2..2

3.0

0.5

0.0

0.0

0.0

0.1

0.2

 PLB vs IMP

1

22.0

1.1

4.0

7.3

1.1

1.4

0.0

2.1

3.2

0.3

0.0

0.5

0.0

4.0

23.8

1.1

9.9

0.6

0.0

2.3

3.2

0.6

0.0

0.0

0.0

11.3

0.3

 PLB vs FLX

2

17.0

0.9

3.1

0.3

39.6

0.1

0.0

1.6

2.4

0.2

0.0

0.4

0.0

3.1

0.2

25.6

0.2

0.4

0.0

1.8

2.4

0.4

0.0

0.0

0.0

0.0

0.2

 PLB vs LIT+IMP

1

22.5

1.1

4.1

3.1

1.1

3.2

0.0

2.1

3.2

0.3

0.0

0.6

0.0

4.1

9.1

1.1

25.3

0.6

0.0

2.4

3.2

0.6

0.0

0.0

0.0

12.1

0.3

 PLB vs ARP

1

0.0

0.0

0.0

0.0

0.0

0.0

100.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

 PLB vs OLZ

2

9.8

0.5

1.8

0.2

0.5

0.1

0.0

53.1

1.4

6.6

0.0

0.2

0.0

1.8

0.1

0.5

0.1

0.3

0.0

14.2

1.4

0.3

0.0

0.0

0.0

0.0

6.6

 PLB vs QTP

2

12.9

0.7

2.4

0.6

0.6

0.1

0.0

1.2

57.7

0.1

0.0

0.3

0.0

2.4

0.2

0.6

0.1

0.3

0.0

1.4

18.2

0.3

0.0

0.0

0.0

0.0

0.1

 PLB vsRisLAI

2

2.8

0.1

0.5

0.0

0.1

0.0

0 0

15.1

0.4

56.3

0.0

0.1

0.0

0.5

0.0

0.1

0.0

0.1

0.0

4.0

0.4

0.1

0.0

0.0

0.0

0.0

19.2

 PLB vs PAL

1

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

100.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

  1. ARP aripiprazole, CBZ carbamazepine, FLX fluoxetine, IMP imipramine, LIT lithium, LTG lamotrigine, OLZ olanzapine, OXC oxcarbazepine, PAL paliperidone, PLB placebo, QTP quetiapine, RisLAI risperidone long-acting injection, VPA valproate